Cambrex and Snapdragon Earn Green Chemistry Honors

The new industrial-scale approach to manufacturing the chiral tetrahydroquinoline core—a vital intermediate for obicetrapib—yields significant environmental benefits. By implementing an organocatalyzed asymmetric Povarov cyclization, the companies reduced process mass intensity by 80% and eliminated aqueous waste entirely. Furthermore, the optimized route cut manufacturing cycle times by 70% and lowered production costs by 50%.

Beyond this chemical breakthrough, Cambrex is expanding its sustainability footprint across its global network. The company’s Milan facility recently secured an EcoVadis Gold rating, ranking it in the top 5% of assessed organizations for ethical and environmental performance. This follows a broader corporate commitment to reduce network-wide greenhouse gas emissions by 50% before 2030.

Simultaneously, Q1 Scientific, a Cambrex subsidiary, has moved to decarbonize its operations in Ireland. Through a corporate power purchase agreement with Flogas, the firm now sources half of its electricity for the Waterford site from the Cronalaght Wind Farm. CEO Thomas Loewald noted that these initiatives reflect a long-term strategy to integrate sustainable manufacturing solutions directly into the drug development lifecycle.